MedPath

Eradication of Malignant Carcinoma in the Breast Tissue

Phase 2
Completed
Conditions
Breast Cancer
Registration Number
NCT02286778
Lead Sponsor
Optimal Health Research
Brief Summary

The purpose of this study is to confirm the findings of an early study and expand our knowledge of treating Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Clinical diagnosis of breast cancer
  • Referred to the study by their treating physician
Exclusion Criteria
  • Any type of treatment for breast cancer before starting the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Number of participants tumor free12 months

assessed by MRI

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.